Blood-based model predicts decline in adults with Down syndrome
The model identified 92.4% of cases that progressed within 16 months and correctly classified 59.9% of cases that remained stable.
Our read
Biomarkers- Studied:
- Cohort study of 246 adults with Down syndrome, 32 months
- What changed:
- The model predicted cognitive decline up to 16 months before clinical progression with an area under the curve of 77.9%
- The catch:
- Only 45 converters were available to evaluate cognitive decline prediction
- Stake:
- An author founded Cx Precision Medicine and holds shares in it.
- In the record:
- The 12th paper on plasma biomarkers with results in people; 58 on record in all.
Editor of record: Boris Djordjevic · AgingResearch.News
Adults with Down syndrome aged 25 or older took part in an observational study that analyzed blood samples from 246 participants assessed at 0, 16 and 32 months. Each prediction covered a 16-month interval beginning when a participant was cognitively stable.
The analysis included 404 observations: 45 involving progression to mild cognitive impairment or Alzheimer's dementia and 359 remaining stable. Mild cognitive impairment meant decline that did not impair daily living skills. Researchers trained a computer model using 25 blood markers and demographic information. They corrected for differences between laboratory batches and narrowed the model to 11 markers plus age and ethnicity. The markers reflected nerve-cell damage, inflammation and blood-vessel health. The refined model predicted progression up to 16 months ahead.
Why it matters
People with Down syndrome face a high risk of Alzheimer's disease, but lifelong intellectual disability complicates early detection. The work addresses whether blood measurements could help assess the risk of impending cognitive decline.
Caveats
Performance was assessed within the same cohort, not validated in a separate population. The predictions covered cognitively stable adults with Down syndrome aged 25 or older, not those already diagnosed with mild cognitive impairment or Alzheimer's dementia.
From the paper
- Participants
The study included 246 participants with blood biomarker assessments at 0, 16, and 32 months.
- Result
… with no significant age‐by‐sex interaction observed (ΔDeviance = 0.86, df = 1, p = 0.35; 95% confidence interval: −0.13 to 0.05) in either the pre‐pool adjustment or post‐pool adjustment analyses.
- Events by group
… conversion rates were 10.1% (22/217) for Trisomy 21, 12.5% (1/8) for Mosaicism, 14.3% (2/14) for Translocation, and 0% (0/1) for Other (χ² = 4.24, df = 6, p = 0.64; Table ); in the 16‐ to 32‐month interval, conversion occurred only among Trisomy 21 participants (13.3%, 20/150) …
- Limitation
(1) Limited Sample Size for Converters: Although the study included 45 Converters, larger sample sizes are needed to improve model generalizability and stability.
Quoted word for word from the full text on PubMed Central.
The paper
University of North Texas Health Science Center
Alzheimer's & Dementia, Jul 2026, Open access
Comments
Be the first to comment.